[
    [
        {
            "time": "2021-12-01",
            "original_text": "The biggest challenges facing vaccine distribution",
            "features": {
                "keywords": [
                    "vaccine",
                    "distribution",
                    "challenges"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "The biggest challenges facing vaccine distribution",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-12-01",
            "original_text": "Why BioCryst, Moderna And More Are Moving Today",
            "features": {
                "keywords": [
                    "BioCryst",
                    "Moderna",
                    "moving"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why BioCryst, Moderna And More Are Moving Today",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-01",
            "original_text": "Coronavirus update: Fauci to become Biden's chief medical adviser; United Health Group to study Eli Lilly antibody",
            "features": {
                "keywords": [
                    "Fauci",
                    "Biden",
                    "United Health Group",
                    "Eli Lilly",
                    "antibody"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "government"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Coronavirus update: Fauci to become Biden's chief medical adviser; United Health Group to study Eli Lilly antibody",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-12-01",
            "original_text": "Eli Lilly Rises on New Trial to Treat Covid in High-Risk Patients",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "trial",
                    "Covid",
                    "High-Risk",
                    "Patients"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly Rises on New Trial to Treat Covid in High-Risk Patients",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-01",
            "original_text": "Vaccines and Approved Antibodies Dim Vir Biotechnology’s Covid Opportunity, Analyst Says",
            "features": {
                "keywords": [
                    "Vaccines",
                    "Antibodies",
                    "Vir Biotechnology",
                    "Covid",
                    "Opportunity"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Vaccines and Approved Antibodies Dim Vir Biotechnology’s Covid Opportunity, Analyst Says",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-12-01",
            "original_text": "Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "PFE",
                    "BNTX",
                    "Vaccine",
                    "UK"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-01",
            "original_text": "Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19",
            "features": {
                "keywords": [
                    "Lilly",
                    "UnitedHealth Group",
                    "pragmatic study",
                    "bamlanivimab",
                    "COVID-19"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-12-01",
            "original_text": "Lilly and UnitedHealth launch trial of COVID-19 antibody",
            "features": {
                "keywords": [
                    "Lilly",
                    "UnitedHealth",
                    "trial",
                    "COVID-19",
                    "antibody"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly and UnitedHealth launch trial of COVID-19 antibody",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]